ArticleOphthalmology2026
Comparing the Utility of Retinal Nerve Fiber Layer and Ganglion Cell Inner Plexiform Layer OCT Changes to Detect Glaucoma Progression.
Article in Ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeMeasure and compare the rates of circumpapillary retinal nerve fiber layer (cpRNFL) and macular ganglion cell-inner plexiform layer (mGCIPL) thinning in glaucomatous eyes with and without visual field (VF) progression, across a broad range of disease severity, in a large clinical population.
designRetrospective, longitudinal study.
participantsA total of 2464 eyes (1605 patients) with longitudinal testing (≥5 reliable cpRNFL, mGCIPL, and VF measurements). All cpRNFL and mGCIPL measurements were within 1 year of a VF test.
methodsWe used linear regression to measure rates of cpRNFL and mGCIPL thinning in suspect, mild, moderate, and advanced glaucoma (severity defined by Hodapp-Parrish-Anderson criteria). We compared thinning rates between eyes with and without VF progression (using trend- or event-based criteria). Next, we used logistic mixed-effects models to estimate the impact of cpRNFL and mGCIPL thinning rates on the probability of VF progression. We used general linear hypothesis testing to assess the effect of cpRNFL and mGCIPL thinning rates in each stage of severity.
main outcome measuresRates of cpRNFL and mGCIPL thinning (μm/year) stratified by disease severity.
resultsThe cpRNFL and mGCIPL thinning rates were significantly faster in progressing eyes (-1.02 and -1.04 μm/year, respectively) than in nonprogressing eyes (-0.41 and -0.41 μm/year, respectively). Differences between progressors and nonprogressors diminished with worsening disease severity. The effect of cpRNFL and mGCIPL thinning on the probability of VF progression was similar overall (2.4% vs. 2.1% increased probability per 1 μm/year faster rate of thinning) but differed depending on the glaucoma severity. The effect of cpRNFL thinning was greatest in glaucoma suspects but was not statistically significant in advanced glaucoma. In contrast, the effect of mGCIPL thinning was smallest in suspects, increased with worsening disease severity, and was still statistically significant in advanced disease.
conclusionsThe cpRNFL and mGCIPL changes serve complementary roles in monitoring glaucoma progression depending on the stage of disease severity. The cpRNFL is more strongly associated with VF progression than mGCIPL in early glaucoma. The mGCIPL is more strongly associated with progression than cpRNFL in later stages of glaucoma. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.